KLKB1

References

Title

Authors

Source

Complete sequencing and characterization of 21,243 full-length human cDNAs

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,

Nat. Genet. 36:40-45(2004)

Generation and annotation of the DNA sequences of human chromosomes 2 and 4

Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., Du H., Wilson R.K.,

Nature 434:724-731(2005)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule

McMullen B.A., Fujikawa K., Davie E.W.,

Biochemistry 30:2050-2056(1991)

Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor

Meijers J.C., Kanters D.H., Vlooswijk R.A., van Erp H.E., Hessing M., Bouma B.N.,

Biochemistry 27:4231-4237(1988)

Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry

Zhang H., Li X.-J., Martin D.B., Aebersold R.,

Nat. Biotechnol. 21:660-666(2003)

Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry

Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D.,

J. Proteome Res. 4:2070-2080(2005)

Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry

Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.,

J. Proteome Res. 8:651-661(2009)

Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr)

Lombardi A.M., Sartori M.T., Cabrio L., Fadin M., Zanon E., Girolami A.,

Thromb. Haemost. 90:1040-1045(2003)

A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region

Katsuda I., Maruyama F., Ezaki K., Sawamura T., Ichihara Y.,

Eur. J. Haematol. 79:59-68(2007)

Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats

Chung D.W., Fujikawa K., McMullen B.A., Davie E.W.,

Biochemistry 25:2410-2417(1986)

Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease

Yu H., Anderson P.J., Freedman B.I., Rich S.S., Bowden D.W.,

Genomics 69:225-234(2000)

Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats.

Chung D.W., Fujikawa K., McMullen B.A., Davie E.W.,

Biochemistry 25:2410-2417(1986)

Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease.

Yu H., Anderson P.J., Freedman B.I., Rich S.S., Bowden D.W.,

Genomics 69:225-234(2000)

Complete sequencing and characterization of 21,243 full-length human cDNAs.

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,

Nat. Genet. 36:40-45(2004)

Generation and annotation of the DNA sequences of human chromosomes 2 and 4.

Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., Du H., Wilson R.K.,

Nature 434:724-731(2005)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule.

McMullen B.A., Fujikawa K., Davie E.W.,

Biochemistry 30:2050-2056(1991)

Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor.

Meijers J.C., Kanters D.H., Vlooswijk R.A., van Erp H.E., Hessing M., Bouma B.N.,

Biochemistry 27:4231-4237(1988)

Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.

Zhang H., Li X.-J., Martin D.B., Aebersold R.,

Nat. Biotechnol. 21:660-666(2003)

Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.

Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D.,

J. Proteome Res. 4:2070-2080(2005)

Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.

Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.,

J. Proteome Res. 8:651-661(2009)

Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr).

Lombardi A.M., Sartori M.T., Cabrio L., Fadin M., Zanon E., Girolami A.,

Thromb. Haemost. 90:1040-1045(2003)

A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region.

Katsuda I., Maruyama F., Ezaki K., Sawamura T., Ichihara Y.,

Eur. J. Haematol. 79:59-68(2007)

Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.

Griffin J.H., Cochrane C.G.,

Proc Natl Acad Sci U S A 73:2554-2558(1976)

Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1.

Joseph K., Shibayama Y., Ghebrehiwet B., Kaplan A.P.,

Thromb Haemost 85:119-124(2001)

Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator.

Shariat-Madar Z., Mahdi F., Schmaier A.H.,

J Biol Chem 277:17962-17969(2002)

Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes.

Mahdi F., Madar Z.S., Figueroa C.D., Schmaier A.H.,

Blood 99:3585-3596(2002)

Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator.

Moreira C.R., Schmaier A.H., Mahdi F., da Motta G., Nader H.B., Shariat-Madar Z.,

FEBS Lett 523:167-170(2002)

Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.

Peek M., Moran P., Mendoza N., Wickramasinghe D., Kirchhofer D.,

J Biol Chem 277:47804-47809(2002)

The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.

Bos I.G.A., Lubbers Y.T.P., Roem D., Abrahams J.P., Hack C.E., Eldering E.,

J. Biol. Chem. 278:29463-29470(2003)

Attenuated kinin release from human neutrophil elastase-pretreated kininogens by tissue and plasma kallikreins.

Dulinski R., Suder P., Guevara-Lora I., Rapala-Kozik M., Potempa J., Silberring J., Imamura T., Travis J., Kozik A.,

Biol Chem 384:929-937(2003)

The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells.

Mahdi F., Shariat-Madar Z., Schmaier A.H.,

J Biol Chem 278:43983-43990(2003)

A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444-->Leu).

Frange D., Aulak K.S., Cicardi M., Harrison R.A., Davis A.E. III,

FEBS Lett. 301:34-36(1992)

The physiologic basis of assembly and activation of the plasma kallikrein/kinin system.

Schmaier A.H.,

Thromb Haemost 91:1-3(2004)

Recombinant prolylcarboxypeptidase activates plasma prekallikrein.

Shariat-Madar Z., Mahdi F., Schmaier A.H.,

Blood 103:4554-4561(2004)

Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein.

Tang J., Yu C.L., Williams S.R., Springman E., Jeffery D., Sprengeler P.A., Estevez A., Sampang J., Shrader W., Spencer J., Young W., McGrath M., Katz B.A.,

J Biol Chem 280:41077-41089(2005)

Crystal structure of the factor XI zymogen reveals a pathway for transactivation.

Papagrigoriou E., McEwan P.A., Walsh P.N., Emsley J.,

Nat Struct Mol Biol 13:557-558(2006)

Common variation in KLKB1 and essential hypertension risk: tagging-SNP haplotype analysis in a case-control study.

Lu X., Zhao W., Huang J., Li H., Yang W., Wang L., Huang W., Chen S., Gu D.,

Hum Genet 121:327-335(2007)

Cellular expression of plasma prekallikrein in human tissues.

Fink E., Bhoola K.D., Snyman C., Neth P., Figueroa C.D.,

Biol Chem 388:957-963(2007)

Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation.

Hooley E., McEwan P.A., Emsley J.,

J Thromb Haemost 5:2461-2466(2007)

Kallikrein activates prothrombin.

Stief T.W.,

Clin Appl Thromb Hemost 14:97-98(2008)

Plasma kallikrein is activated on dermatan sulfate and cleaves factor H.

Saito A.,

Biochem Biophys Res Commun 370:646-650(2008)

Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer.

Chee J., Naran A., Misso N.L., Thompson P.J., Bhoola K.D.,

Biol Chem 389:1225-1233(2008)

Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor.

Joseph K., Tholanikunnel B.G., Kaplan A.P.,

J Allergy Clin Immunol 124:143-149(2009)

Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.

Lee J.Y., Park A.K., Lee K.M., Park S.K., Han S., Han W., Noh D.Y., Yoo K.Y., Kim H., Chanock S.J., Rothman N., Kang D.,

Carcinogenesis 30:1528-1531(2009)

Common variation in genes related to innate immunity and risk of adult glioma.

Rajaraman P., Brenner A.V., Butler M.A., Wang S.S., Pfeiffer R.M., Ruder A.M., Linet M.S., Yeager M., Wang Z., Orr N., Fine H.A., Kwon D., Thomas G., Rothman N., Inskip P.D., Chanock S.J.,

Cancer Epidemiol Biomarkers Prev 18:1651-1658(2009)

Genetic variants associated with deep vein thrombosis: the F11 locus.

Li Y., Bezemer I.D., Rowland C.M., Tong C.H., Arellano A.R., Catanese J.J., Devlin J.J., Reitsma P.H., Bare L.A., Rosendaal F.R.,

J Thromb Haemost 7:1802-1808(2009)

Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Abid K., Rochat B., Lassahn P.G., Stocklin R., Michalet S., Brakch N., Aubert J.F., Vatansever B., Tella P., De Meester I., Grouzmann E.,

J Biol Chem 284:24715-24724(2009)

Management of prekallikrein deficiency during cardiac surgery.

Eeckhoudt S.L., Momeni M., Matta A., Latinne D., Arnout J., Hermans C.,

Thromb Haemost 103:866-867(2010)

Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.

Skriver K., Wikoff W.R., Patston P.A., Tausk F., Schapira M., Kaplan A.P., Bock S.C.,

J Biol Chem 266:9216-9221(1991)

Risk of meningioma and common variation in genes related to innate immunity.

Rajaraman P., Brenner A.V., Neta G., Pfeiffer R., Wang S.S., Yeager M., Thomas G., Fine H.A., Linet M.S., Rothman N., Chanock S.J., Inskip P.D.,

Cancer Epidemiol Biomarkers Prev 19:1356-1361(2010)

Polymorphisms in innate immunity genes and risk of childhood leukemia.

Han S., Lan Q., Park A.K., Lee K.M., Park S.K., Ahn H.S., Shin H.Y., Kang H.J., Koo H.H., Seo J.J., Choi J.E., Ahn Y.O., Chanock S.J., Kim H., Rothman N., Kang D.,

Hum Immunol 71:727-730(2010)

Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.

MacKenzie J.A., Roosa K.A., Gump B.B., Dumas A.K., Bendinskas K.G.,

Appl Physiol Nutr Metab 35:518-525(2010)

Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin).

Suzuki K., Enghild J.J., Morodomi T., Salvesen G., Nagase H.,

Biochemistry 29:10261-10270(1990)

Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene.

Levy N.J., Ramesh N., Cicardi M., Harrison R.A., Davis A.E. III,

Proc. Natl. Acad. Sci. U.S.A. 87:265-268(1990)

Identification of a new P1 residue mutation (444Arg-->Ser) in a dysfunctional C1 inhibitor protein contained in a type II hereditary angioedema plasma.

Aulak K.S., Cicardi M., Harrison R.A.,

FEBS Lett. 266:13-16(1990)

Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.

Joseph K., Tholanikunnel B.G., Bygum A., Ghebrehiwet B., Kaplan A.P.,

J Allergy Clin Immunol 132:470-475(2013)

High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.

Suffritti C., Zanichelli A., Maggioni L., Bonanni E., Cugno M., Cicardi M.,

Clin Exp Allergy 44:1503-1514(2014)

Inhibition of plasma kallikrein by a highly specific active site blocking antibody.

Kenniston J.A., Faucette R.R., Martik D., Comeau S.R., Lindberg A.P., Kopacz K.J., Conley G.P., Chen J., Viswanathan M., Kastrapeli N., Cosic J., Mason S., DiLeo M., Abendroth J., Kuzmic P., Ladner R.C., Edwards T.E., TenHoor C., Sexton D.J.,

J Biol Chem 289:23596-23608(2014)

Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women.

Siegerink B., Rosendaal F.R., Algra A.,

J Thromb Haemost 12:606-613(2014)

The old and the new in prekallikrein deficiency: historical context and a family from Argentina with PK deficiency due to a new mutation (Arg541Gln) in exon 14 associated with a common polymorphysm (Asn124Ser) in exon 5.

Girolami A., Vidal J., Sabagh M., Salagh M., Gervan N., Parody M., Peroni E., Sambado L., Guglielmone H.,

Semin Thromb Hemost 40:592-599(2014)

Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).

Wang J., Matafonov A., Madkhali H., Mahdi F., Watson D., Schmaier A.H., Gailani D., Shariat-Madar Z.,

Curr Mol Med 14:1173-1185(2014)

Genome-wide meta-analyses of plasma renin activity and concentration reveal association with the kininogen 1 and prekallikrein genes.

CKDGen Consortium, Lieb W., Chen M.H., Teumer A., de Boer R.A., Lin H., Fox E.R., Musani S.K., Wilson J.G., Wang T.J., Volzke H., Petersen A.K., Meisinger C., Nauck M., Schlesinger S., Li Y., Menard J., Hercberg S., Wichmann H.E., Vasan R.S.,

Circ Cardiovasc Genet 8:131-140(2015)

CpG mutations in the reactive site of human C1 inhibitor.

Skriver K., Radziejewska E., Silbermann J.A., Donaldson V.H., Bock S.C.,

J Biol Chem 264:3066-3071(1989)

Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes.

Harpel P.C., Lewin M.F., Kaplan A.P.,

J Biol Chem 260:4257-4263(1985)

KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia.

Adamopoulos P.G., Kontos C.K., Papageorgiou S.G., Pappa V., Scorilas A.,

Clin Biochem 48:849-854(2015)

Kallikrein Promotes Inflammation in Human Dental Pulp Cells Via Protease-Activated Receptor-1.

Hayama T., Kamio N., Okabe T., Muromachi K., Matsushima K.,

J Cell Biochem 117:1522-1528(2016)

Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.

de Maat S., Bjorkqvist J., Suffritti C., Wiesenekker C.P., Nagtegaal W., Koekman A., van Dooremalen S., Pasterkamp G., de Groot P.G., Cicardi M., Renne T., Maas C.,

J Allergy Clin Immunol 138:1414-1423.e9(2016)

von Willebrand Factor and Prekallikrein in Plasma Are Associated With Thrombus Volume in Abdominal Aortic Aneurysms.

Ghulam Q.M., Bredahl K.K., Gram J.B., Lonn L., Goetze J.P., Sillesen H.H., Eiberg J.P.,

Vasc Endovascular Surg 50:391-397(2016)

Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Ivanov I., Shakhawat R., Sun M.F., Dickeson S.K., Puy C., McCarty O.J., Gruber A., Matafonov A., Gailani D.,

Thromb Haemost 117:671-681(2017)

Plasma Kallikrein-Dependent Transforming Growth Factor-beta Activation in Patients With Chronic Pancreatitis and Pancreatic Cancer.

Teraoka R., Hara M., Kikuta K., Hirooka Y., Furutani Y., Shimosegawa T., Masamune A., Kojima S.,

Pancreas 46:e20-e22(2017)

Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.

Li Z., Partridge J., Silva-Garcia A., Rademacher P., Betz A., Xu Q., Sham H., Hu Y., Shan Y., Liu B., Zhang Y., Shi H., Xu Q., Ma X., Zhang L.,

ACS Med Chem Lett 8:185-190(2017)

Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney.

Odya C.E., Marinkovic D.V., Hammon K.J., Stewart T.A., Erdos E.G.,

J. Biol. Chem. 253:5927-5931(1978)

Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset.

Gianni P., Loules G., Zamanakou M., Kompoti M., Csuka D., Psarros F., Magerl M., Moldovan D., Maurer M., Speletas M.G., Farkas H., Germenis A.E.,

Int Arch Allergy Immunol 174:200-204(2017)

PKK deletion in basal keratinocytes promotes tumorigenesis after chemical carcinogenesis.

Chen L., Hayden M.S., Gilmore E.S., Alexander-Savino C., Oleksyn D., Gillespie K., Zhao J., Poligone B.,

Carcinogenesis 39:418-428(2018)

Kallikrein Cleaves C3 and Activates Complement.

Irmscher S., Doring N., Halder L.D., Jo E.A.H., Kopka I., Dunker C., Jacobsen I.D., Luo S., Slevogt H., Lorkowski S., Beyersdorf N., Zipfel P.F., Skerka C.,

J Innate Immun 10:94-105(2018)

Factor XII truncation accelerates activation in solution.

de Maat S., Clark C.C., Boertien M., Parr N., Sanrattana W., Hofman Z.L.M., Maas C.,

J Thromb Haemost 17:183-194(2019)

The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate.

Okada Y., Harris E.D. Jr., Nagase H.,

Biochem J 254:731-741(1988)

A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.

Ivanov I., Matafonov A., Sun M.F., Mohammed B.M., Cheng Q., Dickeson S.K., Kundu S., Verhamme I.M., Gruber A., McCrae K., Gailani D.,

Blood 133:1152-1163(2019)

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.

Li C., Voos K.M., Pathak M., Hall G., McCrae K.R., Dreveny I., Li R., Emsley J.,

J Thromb Haemost 17:759-770(2019)

IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.

Ferrone J.D., Bhattacharjee G., Revenko A.S., Zanardi T.A., Warren M.S., Derosier F.J., Viney N.J., Pham N.C., Kaeser G.E., Baker B.F., Schneider E., Hughes S.G., Monia B.P., MacLeod A.R.,

Nucleic Acid Ther 29:82-91(2019)

Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition.

Partridge J.R., Choy R.M., Silva-Garcia A., Yu C., Li Z., Sham H., Metcalf B.,

J Struct Biol 206:170-182(2019)

Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure.

Parikh R.R., Folsom A.R., Misialek J.R., Rosamond W.D., Chang P.P., Tang W., Cushman M.,

Thromb Res 182:89-94(2019)

Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.

Lorthiois E., Roache J., Barnes-Seeman D., Altmann E., Hassiepen U., Turner G., Duvadie R., Hornak V., Karki R.G., Schiering N., Weihofen W.A., Perruccio F., Calhoun A., Fazal T., Dedic D., Durand C., Dussauge S., Fettis K., Adams C.M.,

J Med Chem 63:8088-8113(2020)

Completion of the primary structure of human high-molecular-mass kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication.

Kellermann J., Lottspeich F., Henschen A., Muller-Esterl W.,

Eur. J. Biochem. 154:471-478(1986)

The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Ratnoff O.D., Pensky J., Ogston D., Naff G.B.,

J Exp Med 129:315-331(1969)

Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma.

Kerbiriou D.M., Griffin J.H.,

J Biol Chem 254:12020-12027(1979)

Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.

Verpy E., Couture-Tosi E., Eldering E., Lopez-Trascasa M., Spath P., Meo T., Tosi M.,

J. Clin. Invest. 95:350-359(1995)

Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II.

Suzuki K., Lees M., Newlands G.F., Nagase H., Woolley D.E.,

Biochem J 305:301-306(1995)

Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families.

Tan F., Morris P.W., Skidgel R.A., Erdoes E.G.,

J. Biol. Chem. 268:16631-16638(1993)

A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema.

Ocejo-Vinyals J.G., Leyva-Cobian F., Fernandez-Luna J.L.,

Mol. Med. 1:700-705(1995)

Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Meier H.L., Pierce J.V., Colman R.W., Kaplan A.P.,

J Clin Invest 60:18-31(1977)

Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251.

Zahedi R., Aulak K.S., Eldering E., Davis A.E.,

J Biol Chem 271:24307-24312(1996)

High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.

Lin Y., Harris R.B., Yan W., McCrae K.R., Zhang H., Colman R.W.,

Blood 90:690-697(1997)

High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation.

Motta G., Rojkjaer R., Hasan A.A., Cines D.B., Schmaier A.H.,

Blood 91:516-528(1998)

Synonyms

Description

KO Status

Drug Information

Berotralstat

Lanadelumab

Ecallantide

KVD-900

KVD-001

THR-149

ATN-249

KVD-824

MDPK-67b

NTLA-2002

QLS-215

KVD-818

CU-2010

Avoralstat